Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

被引:12
作者
Abbott, Brian L. [1 ]
机构
[1] Sletten Canc Inst, Dept Med Oncol, Great Falls, MT 59405 USA
关键词
BCR-ABL inhibitor; chronic myelogenous leukemia; chronic myeloid leukemia; dasatinib; first-line; front-line; untreated; CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; HIGH-DOSE IMATINIB; CYTOGENETIC RESPONSES; MOLECULAR RESPONSES; FOLLOW-UP; BCR-ABL; ACCELERATED PHASE; SUBOPTIMAL RESPONSE; RANDOMIZED PHASE-2;
D O I
10.1016/j.clinthera.2012.01.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Imatinib is an effective treatment for patients with newly diagnosed chronic phase chronic myeloid leukemia (CML-CP), but resistance to imatinib can occur. Second-generation BCR-ABL inhibitors have shorter onset times and higher rates of complete cytogenetic response (CCyR) than imatinib. Dasatinib has a half-maximal inhibitory concentration 325 times lower than imatinib for BCR-ABL substrate phosphorylation in vitro and is less susceptible to most known molecular mechanisms of BCR-ABL imatinib resistance. Objectives: This study summarized published data on the use of dasatinib in CML-CP, reviewed the importance of early response to therapy, and discussed additional therapies for patients with newly diagnosed disease. Methods: PubMed was searched through June 2011 for English-language publications with the following search terms: imatinib, dasatinib, nilotinib, chronic myeloid/myelogenous leukemia or CML, and clinical trial. To identify follow-up data from published trials and data on trials in progress and products in development, similar searches were conducted for abstract and clinical trial databases. Relevant articles and abstracts were identified as those reporting results of Phase II and III clinical trials, predictors of treatment response, and treatment guidelines. No prespecified inclusion or exclusion criteria were used. Results: Dasatinib was effective in patients resistant to imatinib and more effective than high-dose imatinib in patients with newly diagnosed CML who were resistant to standard dose imatinib. Compared with imatinib, dasatinib induced superior response rates and patient outcomes earlier in the disease. In a Phase III trial in patients with newly diagnosed CML-CP, dasatinib 100 mg once daily induced significantly higher and faster rates of confirmed CCyR and major molecular response by 12 months versus imatinib and was generally well tolerated. Early achievement of CCyR was associated with better long-term progression-free survival. Dasatinib was approved by the U.S. Food and Drug Administration and the European Medicines Agency for initial treatment of CML-CP. Conclusions: Dasatinib was an effective treatment with the potential to improve long-term outcomes for patients with newly diagnosed CML-CP. (Clin Ther. 2012;34:272-281) (C) 2012 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:272 / 281
页数:10
相关论文
共 50 条
  • [41] Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
    Cervantes, Francisco
    Lopez-Garrido, Pilar
    Montero, Maria-Isabel
    Jonte, Fermin
    Martinez, Jesus
    Hernandez-Boluda, Juan-Carlos
    Calbacho, Maria
    Sureda, Anna
    Perez-Rus, Gloria
    Nieto, Jose B.
    Perez-Lopez, Cristina
    Roman-Gomez, Jose
    Gonzalez, Marcos
    Pereira, Arturo
    Colomer, Dolors
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1317 - 1324
  • [42] Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients
    Li, Yuxin
    Zhang, Yilin
    Wang, Jin
    He, Aili
    Zhang, Wanggang
    Cao, Xingmei
    Chen, Yinxia
    Liu, Jie
    Zhang, Pengyu
    Wang, Jianli
    Zhao, Wanhong
    Yang, Yun
    Meng, Xin
    Chen, Sheping
    Zhang, Longjin
    Wang, Ting
    Wang, Xugeng
    Ma, Xiaorong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [43] Treatment of Chronic Phase Chronic Myeloid Leukemia with Imatinib
    Prasanth Ganesan
    Rejiv Rajendranath
    Vignesh Kandakumar
    Tenali Gnana Sagar
    The Indian Journal of Pediatrics, 2015, 82 : 235 - 239
  • [44] An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China A CHEERS-compliant article
    Wu, Bin
    Liu, Maobai
    Li, Te
    Lin, Houwen
    Zhong, Hua
    MEDICINE, 2017, 96 (29)
  • [45] Targeted treatment of chronic myeloid leukemia: role of imatinib
    Tamascar, Ila
    Ramanarayanan, Jeyanthi
    ONCOTARGETS AND THERAPY, 2009, 2 : 63 - 71
  • [46] Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia
    Mitchell, Birgitta
    Deininger, Michael
    LEUKEMIA & LYMPHOMA, 2011, 52 : 4 - 11
  • [47] Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country
    Hussain, Shabneez
    Shaikh, Mohammad Usman
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2449 - 2457
  • [48] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Ishida, Yoji
    Murai, Kazunori
    Yamaguchi, Kohei
    Miyagishima, Takuto
    Shindo, Motohiro
    Ogawa, Kazuei
    Nagashima, Takahiro
    Sato, Shinji
    Watanabe, Reiko
    Yamamoto, Satoshi
    Hirose, Takayuki
    Saitou, Souich
    Yonezumi, Masakatsu
    Kondo, Takeshi
    Kato, Yuichi
    Mochizuki, Noboru
    Ohno, Keiko
    Kishino, Satoshi
    Kubo, Kohmei
    Oyake, Tatsuo
    Ito, Shigeki
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 185 - 193
  • [49] The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
    Andreas Hochhaus
    Hagop Kantarjian
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1971 - 1984
  • [50] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Yoji Ishida
    Kazunori Murai
    Kohei Yamaguchi
    Takuto Miyagishima
    Motohiro Shindo
    Kazuei Ogawa
    Takahiro Nagashima
    Shinji Sato
    Reiko Watanabe
    Satoshi Yamamoto
    Takayuki Hirose
    Souich Saitou
    Masakatsu Yonezumi
    Takeshi Kondo
    Yuichi Kato
    Noboru Mochizuki
    Keiko Ohno
    Satoshi Kishino
    Kohmei Kubo
    Tatsuo Oyake
    Shigeki Ito
    European Journal of Clinical Pharmacology, 2016, 72 : 185 - 193